Selected Grants
Long-term safety and tolerability of TAK-881 in subjects with Primary Immunodeficiency Diseases
Clinical TrialPrincipal Investigator · Awarded by Takeda Development Center Americas, Inc · 2024 - 2027A Phase III, Open-label, Prospective, Multicenter Study to Assess Efficacy, Safety of Kedrion
Clinical TrialPrincipal Investigator · Awarded by Kedrion S.p.A. · 2025 - 2027Developing a National Registry for Female Carriers of X-linked Chronic Granulomatous Disease: Improving Recognition, Diagnosis, and Treatment
ResearchMentor · Awarded by American College of Allergy, Asthma & Immunology · 2024 - 2026Multicenter, Prospective, Open-label, Randomized, Crossover Study to Evaluate Pharmacokinetics (PK), Safety, and Tolerability of TAK-881 in Primary Immunodeficiency Diseases (PIDD)
Clinical TrialPrincipal Investigator · Awarded by Takeda Development Center Americas, Inc · 2024 - 2026External Relationships
- American Academy of Pediatrics
- CME Outfitters Inc
- CSL Behring LLC
- Cycle Pharmaceuticals
- Grifols
- Horizon Therapeutics (purchased Viela Bio) and acquired by Amgen
- INfectious Diseases Society of America
- Janssen Pharmaceuticals
- Neuroimmune Foundation
- North Carolina Allergy, Asthma and Immunology Society
- Novartis pharmaceuticals
- Pfizer Inc.
- Pharming Healthcare, Inc
- Southeastern Allergy, Asthma, and Immunology Society
- Takeda Pharmaceutical Co. Ltd.
- X4 Pharmaceuticals
- adma biologics
- american college of allergy, asthma, and immunology
This faculty member (or a member of their immediate family) has reported outside activities with the companies, institutions, or organizations listed above. This information is available to institutional leadership and, when appropriate, management plans are in place to address potential conflicts of interest.